As ATUM’s Co-Founder, Dr. Claes Gustafsson oversees most of the company’s external communications and is actively engaged in developing ATUM's technology platforms. Prior to co-founding ATUM in 2003, Claes managed key strategic teams at Maxygen Inc and worked as a scientist at Kosan Biosciences, and post-doctoral positions at UCSC and UCSF. He received his Ph.D. in Molecular Biology/Biochemistry from the University of Umeå, Sweden.
ATUM leverages its integrated gene design, synthesis, protein engineering, and cell line development platforms to accelerate the discovery, optimization, and manufacturing of bispecific antibodies. The platform enables rapid prototyping and functional screening of diverse bispecific formats. This talk will highlight case studies demonstrating how ATUM’s platform facilitates the efficient development of bispecific antibodies.